<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715635</url>
  </required_header>
  <id_info>
    <org_study_id>15/LO/0789</org_study_id>
    <nct_id>NCT02715635</nct_id>
  </id_info>
  <brief_title>Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate on a Model of Vascular Dysfunction in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal research objective is to determine whether inorganic nitrate in the form of
      beetroot juice compared to placebo control prevents the systemic inflammation that underlies
      typhoid vaccine-induced endothelial dysfunction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We wish to determine in a prospective manner whether inorganic nitrate affects the
      endothelial dysfunction induced by systemic inflammation. At baseline we will measure
      flow-mediated dilatation (FMD) and peripheral augmentation index, as well as aortic
      stiffness, as measured by pulse wave velocity (PWV). Volunteers will then receive ~8 mmols of
      dietary nitrate or nitrate free placebo juice once daily for 6 days. After this, depending on
      availability, volunteers will receive a typhoid vaccine Typherix®, GlaxoSmithKline UK or
      Typhim Vi ™, AAH Pharmaceuticals Ltd). This vaccine generates a mild systemic inflammation
      that is associated with vascular dysfunction. All vascular function measures will be repeated
      at 8 hours and 32 hours after vaccine administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilatation</measure>
    <time_frame>Day 1, Day 7 (8 hours post typhoid vaccine), Day 8 (32 hours post typhoid vaccine)</time_frame>
    <description>Comparison of change in FMD from baseline after typhoid vaccination following inorganic nitrate versus placebo supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nitrite concentration</measure>
    <time_frame>Day 1, Day 7 (8 hours post typhoid vaccine), Day 8 (32 hours post typhoid vaccine)</time_frame>
    <description>Comparison of change in plasma nitrite concentration following inorganic nitrate versus placebo supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of acute inflammation</measure>
    <time_frame>Day 1, Day 7 (8 hours post typhoid vaccine), Day 8 (32 hours post typhoid vaccine)</time_frame>
    <description>Comparison of change in peripheral markers of inflammation and leucocyte count following nitrate versus placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>Day 1, Day 7 (8 hours post typhoid vaccine), Day 8 (32 hours post typhoid vaccine)</time_frame>
    <description>Comparison of change in PWV from baseline after typhoid vaccination following nitrate versus placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>Day 1, Day 7 (8 hours post typhoid vaccine), Day 8 (32 hours post typhoid vaccine)</time_frame>
    <description>Comparison of change in platelet reactivity from baseline after typhoid vaccination following nitrate versus placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma nitrate concentration</measure>
    <time_frame>Day 1, Day 7 (8 hours post typhoid vaccine), Day 8 (32 hours post typhoid vaccine)</time_frame>
    <description>Comparison of change in plasma nitrate concentration following inorganic nitrate versus placebo supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Nitrate-rich beetroot juice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®
Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrate-deplete beetroot juice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®
Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Typhoid vaccine</intervention_name>
    <description>The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution</description>
    <arm_group_label>Nitrate-rich beetroot juice</arm_group_label>
    <arm_group_label>Nitrate-deplete beetroot juice</arm_group_label>
    <other_name>Typhim Vi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Concentrate beetroot Juice</intervention_name>
    <description>140 ml containing ~8 mmol of inorganic nitrate</description>
    <arm_group_label>Nitrate-rich beetroot juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Concentrate beetroot Juice (Placebo)</intervention_name>
    <description>140 ml which is nitrate-depleted</description>
    <arm_group_label>Nitrate-deplete beetroot juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers

          2. Aged 18-45

          3. Volunteers who are willing to sign the consent form.

          4. Normal resting blood pressure (&lt;140/90 mmHg)

        Exclusion Criteria:

          1. Healthy subjects unwilling to consent

          2. Pregnant, or any possibility that a subject may be pregnant unless in the latter case
             a pregnancy test is performed with a negative result

          3. History of any serious illnesses, including recent infections or trauma

          4. Subjects taking systemic medication (other than the oral contraceptive pill)

          5. Subjects with self-reported use of mouthwash or tongue scrapes

          6. Subjects with recent (3 months) or current antibiotic use

          7. Subjects with a history, or recent treatment of (within last 3 months) any oral
             condition (excluding caries), including gingivitis, periodontitis and halitosis

          8. Subjects with a history of typhoid vaccination in the last 6 months

          9. Subjects with any history of a blood-borne infectious disease such Hepatitis B or C
             virus, or HIV
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Ahluwalia, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amrita Ahluwalia, BSc PhD</last_name>
    <phone>0207 882 8377</phone>
    <email>a.ahluwalia@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Krishnaraj S Rathod, BMedSci MBBS</last_name>
    <phone>0207 882 8931</phone>
    <email>k.s.rathod@qmul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Harvey Research Institute, Barts and The London School of Medicine</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishnaraj Rathod, BMedSci MBBS</last_name>
      <phone>0207 882 8931</phone>
      <email>k.s.rathod@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Amrita Ahluwalia, BSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krishnaraj S Rathod, BMedSci MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vikas Kapil, MBChB PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rayomand S Khambata, BSc PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, Deanfield JE, MacAllister RJ, Vallance P. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000 Aug 29;102(9):994-9.</citation>
    <PMID>10961963</PMID>
  </reference>
  <reference>
    <citation>Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, Vallance P. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation. 2002 Jun 4;105(22):2600-4.</citation>
    <PMID>12045164</PMID>
  </reference>
  <reference>
    <citation>Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ, Millasseau SC, Deanfield JE, Halcox JP. Non-invasive assessment of endothelial function: which technique? J Am Coll Cardiol. 2006 Nov 7;48(9):1846-50. Epub 2006 Oct 17.</citation>
    <PMID>17084260</PMID>
  </reference>
  <reference>
    <citation>Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, MacAllister RJ. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004 Oct 1;64(1):172-8.</citation>
    <PMID>15364625</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary University of London</investigator_affiliation>
    <investigator_full_name>Amrita Ahluwalia</investigator_full_name>
    <investigator_title>Deputy Director of The William Harvey Research Institute, Prof of Vascular Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

